Arvinas, Inc.

Healthcare · Biotechnology · United States

Last price 7.86 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 513.94M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such...